Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with "Stop-And-Go" Osimertinib.

Internal medicine (Tokyo, Japan) - 1 Apr 2018

Kobayashi Keigo, Naoki Katsuhiko, Kuroda Aoi, Yasuda Hiroyuki, Kawada Ichiro, Soejima Kenzo, Betsuyaku Tomoko

Abstract excerpt

A 69-year-old man with post-operative recurrence of lung adenocarcinoma was treated with multiple chemotherapies, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A second biopsy revealed an EGFR T790M mutation. As 10th-line chemotherapy, osimertinib was initiated. After 24 weeks, chest computed tomography (CT) revealed asymptomatic ground-glass opacities in both lobes. After four...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Adenocarcinoma of Lung

Share to Aniline Compounds

Share to Antineoplastic Agents

Share to Carcinoma, Non-Small-Cell Lung

Share to Neoplasm Recurrence, Local

Share to Piperazines

Source

Open in PubMed Open full text

Identifiers

PMID: 29269665
DOI: 10.2169/internalmedicine.9609-17
PMCID: PMC5919862

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with "Stop-And-Go" Osimertinib.PMID 29269665Read ↗

Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non-small cell lung cancer: A case report.Semantic proximity Read ↗

Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature.Semantic proximity Read ↗

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease.Semantic proximity Read ↗

Postoperative EGFR-TKI treatment on residual multiple ground-glass nodules after resection for lung adenocarcinoma:a case report and literature reviewSemantic proximity Read ↗

EGFR Mutation Rates Correlate with Age at Diagnosis and Tumor Characteristics in Patients with Pulmonary Ground-Glass OpacitiesSemantic proximity Read ↗

Prognostic influence of epidermal growth factor receptor mutation and radiological ground glass appearance in patients with early-stage lung adenocarcinoma.Semantic proximity Read ↗

Osimertinib showed efficacy on contralateral multiple ground-glass nodules after segmentectomy for lung adenocarcinoma harboring primary EGFR-T790M mutation: a case report and review of the literature.Semantic proximity Read ↗

TAPO in first-line osimertinib therapy and continuation of osimertinib.Semantic proximity Read ↗

Early metastasis detected in patients with multifocal pulmonary ground-glass opacities (GGOs).Semantic proximity Read ↗

Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.Semantic proximity Read ↗

Postoperative EGFR-TKI treatment on residual multiple ground-glass nodules after resection for lung adenocarcinoma: a rare case report and literature reviewSemantic proximity Read ↗

Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.